The global AI in pharmaceutical market is on the cusp of an extraordinary surge, with a projected valuation of US$4,451.6 Mn by 2030, representing a substantial increase from approximately US$807.2 Mn in 2018. This momentous growth is underpinned by the widespread adoption of Artificial Intelligence (AI) across the pharmaceutical sector, ushering in a new era of innovation in drug discovery, development, and personalized healthcare.
Read More: https://www.fairfieldmarketresearch.com/report/ai-in-pharmaceutical-market
Between 2023 and 2030, the market is expected to achieve a remarkable Compound Annual Growth Rate (CAGR) of 19.1%, highlighting AI’s pivotal role in reshaping the pharmaceutical landscape.
A Renaissance in Pharmaceutical Advancements
The integration of AI into the pharmaceutical industry marks a transformative shift in innovation, empowering researchers and healthcare professionals to make data-driven decisions, reduce costs, and enhance patient outcomes. This revolutionary transition is set to redefine drug discovery, making it more efficient, cost-effective, and precise.
Key Market Highlights
1. Redefining Drug Discovery and Development
AI is at the forefront of redefining drug discovery and development, leveraging data analytics, machine learning, and natural language processing. By accelerating research processes, AI significantly reduces costs and enhances the likelihood of developing effective medications. As AI technologies continue to advance, their impact on reshaping the pharmaceutical sector becomes increasingly prominent.
2. Key Report Findings
- The global AI in pharmaceutical market is projected to reach US$4,451.6 Mn by 2030, surging from US$807.2 Mn in 2018.
- The growing integration of AI in drug discovery and development, predictive forecasting, pharmaceutical marketing, and personalized treatment are pivotal drivers of this growth.
- Asia Pacific is poised to be the fastest-growing market, with North America maintaining a leading position.
3. Driving Forces
Unleashing Potential in New Drug Discovery AI has emerged as an indispensable tool in the pharmaceutical sector, particularly in the era of the COVID-19 pandemic. It facilitates the precise identification of disease patterns, leading to the discovery of optimal drug compositions. Embracing AI reduces research and development costs, minimizes errors, and accelerates drug development, resulting in cost-effective and efficacious medicines.
Rapid Adoption of AI in Drug Discovery and Development AI is increasingly integrated into drug discovery and development processes. It analyzes vast datasets to identify potential drug targets, optimize drug molecules, and predict efficacy and safety. AI also plays a pivotal role in identifying biomarkers for personalized treatment and expediting drug development.
Thriving Personalized Treatment Enabled by Advanced Technology AI empowers healthcare professionals to provide personalized treatment through real-time patient data analysis. Machine learning and AI-driven data analysis offer early insights into patient conditions, enhancing diagnostic capabilities. Predictive forecasting, clinical trial optimization, and pharmaceutical marketing also benefit from AI, propelling market growth.
4. Segment Analysis
Drug Discovery: Pioneering the Transformation The drug discovery segment is a major contributor to the AI in pharmaceutical market, valued at US$291.7 Mn in 2022 and projected to reach approximately US$1,225.9 Mn by 2030. AI’s influence in drug discovery spans target identification, clinical trials, and molecular pathway analysis, resulting in significantly improved efficiency and success rates.
Natural Language Processing: Dominant Technology Segment Natural language processing (NLP) is a critical technology in the pharmaceutical industry, enabling the extraction, organization, and analysis of unstructured text data. NLP expedites the identification of drug candidates, targets, and biological pathways, accelerating drug discovery.
5. Regional Growth Opportunities
North America Leading the Way North America, a global technology hub, is expected to hold a substantial share in the AI in pharmaceutical market. AI applications in clinical trials, drug discovery, and drug development, combined with the growing burden of chronic diseases, are driving market growth. Industry leaders and cross-industry collaborations further bolster the region’s position.
The United States Takes the Lead in Investment Global investment in AI in the pharmaceutical industry is surging, with the United States taking the lead. Investment is projected to reach US$6.3 Bn by 2025, with nearly half of the total coming from the US. China, the UK, Germany, France, and Japan are also actively investing in AI to enhance drug discovery and development capabilities.
Asia Pacific: The Fastest Growing Region The Asia Pacific region is experiencing rapid growth, with a CAGR of 20.8%. AI adoption in the pharmaceutical industry is gaining momentum, particularly in countries like China, Japan, India, and South Korea. AI is accelerating drug discovery, optimizing drug designs, and tailoring treatment plans to individual patients’ characteristics. The region’s focus on precision medicine and AI-driven drug repurposing further fuels growth.
6. Competitive Landscape
The AI in pharmaceutical market is characterized by intense competition, with companies and research institutions leveraging AI to advance drug discovery, development, and patient care. Key players include GNS Healthcare, Benevolent AI, Berg Health, Novo Nordisk, IBM Corporation, Alphabet Inc (DeepMind), General Electric Company, Pfizer Inc., Johnson & Johnson, and Novartis AG.
Our Trending Blogs:
https://hackmd.io/@E4v1isUnROG4-prBVaQQGw/H1VaixRC2
Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
